10月27日 - ** 药物开发商Revolution Medicines RVMD.O股价盘前上涨3.1%至56.21美元
** 公司称美国FDA授予胰腺癌实验性疗法daraxonrasib孤儿药资格
** 美国 FDA 授予 Daraxonrasib 公司孤儿药资格，以促进治疗美国少于 20 万人的罕见疾病的药物开发。
** Daraxonrasib 可阻断 90% 以上胰腺癌病例中发现的 RAS 基因突变 - RVMD
** 公司称正在进行二线转移性胰腺癌晚期试验
** 截至上次收盘，股价年累计上涨约 25
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.